← Leaderboards
Phyllis J. Kanki
Harvard University (Sch Of Public Hlth)
$6,302,335
Attributed
$8,732,344
Total exposure
6
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $734.1K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,354,602 · 5
CDC$1,377,742 · 1
By mechanism
R01$4,161,564 · 3
T32$2,775,588 · 1
U01$1,377,742 · 1
R21$417,450 · 1
Top collaborators
- Dyann F Wirth12 shared
- Oche Ochai Agbaji5 shared
- Eric Joseph Rubin5 shared
- Sarah M Fortune2 shared
- Helen H Lee1 shared
Most similar at Harvard University (Sch Of Public Hlth)
Same institution · by research overlap
- Marcello Pagano$14,152,532
- Carla M Obermeyer$3,540,059
- Sherri O Stuver$4,069,332
- Amitinder Kaur$35,271,713
- Marc J Lallemant$19,725,823
Others in their field
Top investigators on “Human Immunodeficiency Virus 1”
- Constance Ann Benson · University Of California, San Diego$122,634,267
- Barton F Haynes · Duke University$106,892,200
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$103,430,446
- George R Seage · Abt Associates, Inc.$96,260,237
- Dennis R. Burton · Scripps Research Institute$73,539,073
- Rama Rao Amara · Emory University$62,827,078
Research focus
Human Immunodeficiency Virus 1Human Immunodeficiency Virus 2Human SubjectCellular ImmunityClinical ResearchFemaleAfricaAfricanCross ImmunityCommunicable DiseasesHiv InfectionsProstitutionProgramsCytotoxic T LymphocyteAids /Hiv TestEpidemiologyAids Education /PreventionSexually Transmitted DiseasesCommunicable Disease TransmissionChemokineLeukocytesHost Organism InteractionEpitope MappingDisease /Disorder Proneness /Risk
Grant awards (31)
The Graduate Program in Tropical Infectious Diseases$325,806
T32 · FY2025 · AI
The Graduate Program in Tropical Infectious Diseases$322,863
T32 · FY2024 · AI
The Graduate Program in Tropical Infectious Diseases (GPiTID)$207,831
T32 · FY2023 · AI
The Graduate Program in Tropical Infectious Diseases (GPiTID)$202,834
T32 · FY2022 · AI
The Graduate Program in Tropical Infectious Diseases (GPiTID)$193,428
T32 · FY2021 · AI
The Graduate Program in Tropical Infectious Diseases (GPiTID)$189,894
T32 · FY2020 · AI
Zika Virus in Pregnancy in Nigeria$181,350
R21 · FY2020 · AI · contact PI
Reaching 90% target of HIV viral suppression: The role of point of care VL monitoring in resources constrained settings$1
U01 · FY2020 · GH
Zika Virus in Pregnancy in Nigeria$236,100
R21 · FY2019 · AI · contact PI
The Graduate Program in Tropical Infectious Diseases (GPiTID)$178,549
T32 · FY2019 · AI
Reaching 90% target of HIV viral suppression: The role of point of care VL monitoring in resources constrained settings$1
U01 · FY2019 · GH
Reaching 90% target of HIV viral suppression: The role of point of care VL monitoring in resources constrained settings$380,026
U01 · FY2018 · GH
Doctoral Training Program in Tropical Diseases$224,728
T32 · FY2018 · AI
Reaching 90% target of HIV viral suppression: The role of point of care VL monitoring in resources constrained settings$498,857
U01 · FY2017 · GH
Doctoral Training Program in Tropical Diseases$235,238
T32 · FY2017 · AI
Reaching 90% target of HIV viral suppression: The role of point of care VL monitoring in resources constrained settings$498,857
U01 · FY2016 · GH
Doctoral Training Program in Tropical Diseases$233,119
T32 · FY2016 · AI
Doctoral Training Program in Tropical Diseases$231,848
T32 · FY2015 · AI
Doctoral Training Program in Tropical Diseases$229,450
T32 · FY2014 · AI
CORRELATES OF HIV-1 PROTECTION$355,439
R01 · FY2004 · AI
CORRELATES OF HIV-1 PROTECTION$345,088
R01 · FY2003 · AI
HIV-2 CELLULAR IMMUNITY CROSS-REACTIVE WITH HIV-1$323,657
R01 · FY2003 · AI
HIV-2--A MODEL OF HIV PRIMARY INFECTION$425,838
R01 · FY2002 · AI
CORRELATES OF HIV-1 PROTECTION$335,037
R01 · FY2002 · AI
HIV-2 CELLULAR IMMUNITY CROSS-REACTIVE WITH HIV-1$301,908
R01 · FY2002 · AI
HIV-2--A MODEL OF HIV PRIMARY INFECTION$413,833
R01 · FY2001 · AI
CORRELATES OF HIV-1 PROTECTION$327,377
R01 · FY2001 · AI
HIV-2 CELLULAR IMMUNITY CROSS-REACTIVE WITH HIV-1$305,394
R01 · FY2001 · AI
HIV-2--A MODEL OF HIV PRIMARY INFECTION$401,859
R01 · FY2000 · AI
CORRELATES OF HIV-1 PROTECTION$329,632
R01 · FY2000 · AI
HIV-2 CELLULAR IMMUNITY CROSS-REACTIVE WITH HIV-1$296,502
R01 · FY2000 · AI